首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Current developments in pharmacological therapeutics for chronic constipation
【2h】

Current developments in pharmacological therapeutics for chronic constipation

机译:慢性便秘药理学的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic constipation is a common gastrointestinal disease severely affecting the patient׳s quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride, the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field.
机译:慢性便秘是一种常见的胃肠道疾病,严重影响患者的生活质量。便秘的传统治疗方法是使用泻药。最近,包括鲁比前列酮,利那洛肽和普鲁卡必利在内的几种新药已被批准用于治疗慢性便秘。但是,仍然存在严重的未满足的医疗需求,尤其是在那些因当前疗法而效果不佳的患者中。 5-HT4受体调节剂velusetrag和naronapride,鸟苷酸环化酶C激动剂plecanatide和回肠胆汁酸转运蛋白抑制剂elobixibat被认为是研究中最有前途的药物。在此,我们对用于治疗慢性便秘的药理学方法进行了全面综述,目的是反映该领域药物的发展趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号